Authors
Maud Maillard, Matthieu Gracia, Bastien Cabarrou, Félicien Le Louedec, Christelle Moreau, Mathieu Landry, Aurélie Brice, Thierry Lafont, Deniz Ozdin, Ben Allal, Diego Tosi, Gwenaelle Gravis, Guilhem Roubaud, Frédéric Thuillier, Helen Boyle, Florent Puisset, Mélanie White-Koning, Anne Pradines, Etienne Chatelut, Loïc Mourey, Fabienne Thomas
Published in
British journal of clinical pharmacology. Nov 16, 2026. Epub Nov 16, 2026.
Abstract
Sunitinib and pazopanib are anti-angiogenic tyrosine kinase inhibitors (TKIs) used for metastatic renal cancer, with substantial interindividual variability in drug response. This study aimed to explore factors explaining this variability.
Pharmacokinetics (PK) and pharmacogenomics (PG) data from 47 patients enrolled in the SUP-R clinical trial (NCT02555748) were analysed retrospectively (32 treated with sunitinib, 15 with pazopanib). Plasma concentrations measured during the first two treatment cycles were analysed using a non-linear mixed effects model. Exploratory analyses of factors influencing drug exposure, toxicity and efficacy were conducted, including a PG investigation of drug disposition, and target genes and baseline circulating microRNA levels. No correction for multiple comparisons was applied.
The PK models adequately described plasma concentration over time in the cohort. Patients experiencing severe toxicity (≥ Grade 3, CTCAE) showed reduced apparent sunitinib clearance (median 24.3 L/h [11.1-45.7] vs. 32.4 L/h [16.6-90.6], p = 0.006). Responders were more exposed to sunitinib and active metabolite SU12662 (observed Ctrough,ss = 140.1 ng/mL [43.2-209.5] vs. 89.5 ng/mL [4.3-230.7], p = 0.036); similar trends were observed with pazopanib, though limited events (3 responders/10 evaluable) precluded definitive interpretation. Carriers of at least one variant ABCB1 c.1199G>A allele were more likely to respond to TKI treatment (odd-ratio = 10.8, 95% confidence interval [1.7-69.9], p = 0.012).
This study assessed the exposure-response relationships of both drugs and identified potential factors to consider in case of toxicity or treatment failure.
PMID:
43036976
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0